Simcere Pharmaceutical Group (SCR) Misses Q3 EPS by 5c, Sales Fall Short
Tweet
Share
E-mailGet Alerts SCR Hot Sheet
Join SI Premium – FREE
Simcere Pharmaceutical Group (NYSE: SCR) reported Q3 EPS of $0.10, $0.05 worse than the analyst estimate of $0.15. Revenue for the quarter came in at $78.5 million versus the consensus estimate of $94.66 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Newton Golf Company (NWTG) Reports Q2 Loss of $0.49
- Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
